Acquisition Strengthens Aspire Pharma’s Strategic Portfolio
Friday, October 17, 2025
Aspire Pharma Ltd, a rapidly growing UK-based specialty generics business, today announces the acquisition of Charlwood Pharma Ltd, a privately owned company specialising in the research & development of niche generic medicines.
The acquisition marks the culmination of a successful multi-year collaboration between the two organisations.
Charlwood brings to Aspire a robust pipeline of products spanning mental health, ear, nose and throat (ENT), cardiovascular and respiratory therapy areas - complementing Aspire’s existing portfolio and growth strategy.
Richard Condon, Aspire Pharma Chief Executive, said: “This acquisition not only strengthens our existing portfolio, but also stands as a testament to the value of long-term partnerships with Aspire, which deliver meaningful innovations that enhance patient care.
“Under the terms of this agreement, Aspire will assume full ownership of all intellectual property, which reinforces our ambitions for international expansion.
“This acquisition further demonstrates Aspire’s commitment to delivering quality, affordable medicines that support the highest levels of patient care, while offering true value to healthcare systems throughout the world.”
About Aspire Pharma
Aspire was established with a simple mission: To make a difference to the lives of patients through the development and supply of innovative products and medicines throughout the world. Aspire is present in the specialty, niche generics, branded generics, and medical device sectors. Aspire was majority acquired by an affiliate of H.I.G. Capital (“H.I.G.”) in 2021. For more information, go to: www.aspirepharma.com.
About H.I.G. Capital
H.I.G. Capital is a leading global alternative investment firm with $70 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach. For more information, please refer to the H.I.G. website at hig.com.
Disclosure Notice
The information contained in this release is correct as of 17th October 2025. Aspire assumes no obligation to update forward‐looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Aspire’s acquisition that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realise the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realised; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavourable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when license applications may be filed in any jurisdictions; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, the product(s) will be commercially successful.
Media Contact
Email: pressoffice@aspirepharma.com.
Tel: +44 1730 231148
